Home › NCT07407777
Evaluation of Gut-Related Well-Being and Mood Effects of a Daily Nutritional Food Ingredient From the Co-Fermentation of Fungal Mycelium (Pleurotus Pulmonarius) and Microalgae (Chlorella Vulgaris)
Evaluation of Gut-Related Well-Being and Mood Effects of a Daily Nutritional Food Ingredient From the Co-Fermentation of Fungal Mycelium (Pleurotus Pulmonarius) and Microalgae (Chlorella Vulgaris) in Healthy Adults Experiencing Minor Gastrointestinal Discomfort: A 30-Day, Two-Arm, Open-Label Study
Who can join
Ages 18 and older · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: Adults aged 18 years or older Generally healthy individuals Experience minor, non-clinical gastrointestinal discomfort at least twice per week for ≥3 months Willing to consume the study product once daily for 30 days Able to dissolve and consume the powdered product in a beverage Able to read, understand, and complete electronic questionnaires in English Access to a smartphone or computer for study participation Provide electronic informed consent Exclusion Criteria: * Diagnosed gastrointestinal disease (e.g., IBS, IBD, GERD requiring medication) Use of medications affecting gastrointestinal function or mood within the past 30 days Initiation of new gut-, immune-, or mood-related supplements within 15 days prior to study start Known allergy or sensitivity to study product components Pregnancy or breastfeeding Major chronic medical condition that could interfere with study participation or data interpretation Participation in another interventional clinical study within the past 30 days Inability or unwillingness to comply with study procedures
About the study
The purpose of the study is to evaluate the gut-related well-being and mood effects of a food ingredient obtained from the co-fermentation of oyster mushroom mycelium (Pleurotus pulmonarius), microalgae (Chlorella vulgaris), and bamboo fibre in healthy adults (aged 18+) experiencing minor gastrointestinal discomfort during an intervention period of 30 days. The participants will be allocated into two unbalanced groups to determine relationships between the measurable outcomes and the dose levels at three different time points: start of the study (baseline), 15 days (middle), and 30 days (end-point), during which participants will be asked to complete GSRS and POMS-2-SF questionnaire
What is being tested
- Food ingredient of oyster mushroom mycelium (Pleurotus pulmonarius) and microalgae (Chlorella vulgaris) (dietary supplement)
Sponsor: Koralo GmbH · Participants: 80 · Started: Jan 19, 2026
Contact the study team
- Guido Albanese, PhD · Phone: +49 163 9144333
Official record on ClinicalTrials.gov — NCT07407777
Locations in the U.S.
| California | Alethios, Inc., San Francisco |
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.